393 related articles for article (PubMed ID: 33221868)
1. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
Meriglier E; Rivoisy C; Hessamfar M; Bernard N; Aureau I; Lapoirie J; Contis A; Sacher F; Sacristan B; Lahouati M; Pedeboscq S; Vandenhende MA; Bouchet S; Bonnet F
J Antimicrob Chemother; 2021 Jan; 76(2):482-486. PubMed ID: 33221868
[TBL] [Abstract][Full Text] [Related]
2. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
[TBL] [Abstract][Full Text] [Related]
3. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
Moschini L; Loffi M; Regazzoni V; Di Tano G; Gherbesi E; Danzi GB
Heart Vessels; 2021 Jan; 36(1):115-120. PubMed ID: 32676695
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
[TBL] [Abstract][Full Text] [Related]
6. Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.
Schneider J; Jaenigen B; Wagner D; Rieg S; Hornuss D; Biever PM; Kern WV; Walz G
PLoS One; 2021; 16(5):e0249760. PubMed ID: 33974624
[TBL] [Abstract][Full Text] [Related]
7. Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
Baralić K; Jorgovanović D; Živančević K; Antonijević Miljaković E; Antonijević B; Buha Djordjevic A; Ćurčić M; Đukić-Ćosić D
Toxicol Appl Pharmacol; 2020 Nov; 406():115237. PubMed ID: 32920000
[TBL] [Abstract][Full Text] [Related]
8. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
[TBL] [Abstract][Full Text] [Related]
9. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
[TBL] [Abstract][Full Text] [Related]
10. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
Gourieux B; Reisz F; Belmas AS; Danion F; Fourtage M; Nai T; Reiter-Schatz A; Ruch Y; Walther J; Nivoix Y; Michel B
Eur J Hosp Pharm; 2021 Sep; 28(5):242-247. PubMed ID: 33239282
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
12. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
14. Smartphone electrocardiogram for QT interval monitoring in Coronavirus Disease 2019 (COVID-19) patients treated with Hydroxychloroquine.
Andy Ko TY; Chen LS; Pang IX; Ling HS; Wong TC; Sia Tonnii LL; Koh KT
Med J Malaysia; 2021 Mar; 76(2):125-130. PubMed ID: 33742617
[TBL] [Abstract][Full Text] [Related]
15. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
Zequn Z; Yujia W; Dingding Q; Jiangfang L
Eur J Pharmacol; 2021 Feb; 893():173813. PubMed ID: 33345848
[TBL] [Abstract][Full Text] [Related]
16. Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients.
Chouchana L; Boujaafar S; Gana I; Preta LH; Regard L; Legendre P; Azoulay C; Canouï E; Zerbit J; Carlier N; Terrier B; Kernéis S; Batista R; Treluyer JM; Zheng Y; Benaboud S
Ther Drug Monit; 2021 Feb; 43(1):131-135. PubMed ID: 33230045
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J
Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712
[TBL] [Abstract][Full Text] [Related]
18. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Kalantari S; Fard SR; Maleki D; Taher MT; Yassin Z; Alimohamadi Y; Minaeian S
J Med Virol; 2021 Dec; 93(12):6557-6565. PubMed ID: 34255369
[TBL] [Abstract][Full Text] [Related]
19. Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study.
Elmekaty EZI; Alibrahim R; Hassanin R; Eltaib S; Elsayed A; Rustom F; Mohamed Ibrahim MI; Abu Khattab M; Al Soub H; Al Maslamani M; Al-Khal A
PLoS One; 2022; 17(5):e0267884. PubMed ID: 35507606
[TBL] [Abstract][Full Text] [Related]
20. Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Bartiromo M; Borchi B; Botta A; Bagalà A; Lugli G; Tilli M; Cavallo A; Xhaferi B; Cutruzzulà R; Vaglio A; Bresci S; Larti A; Bartoloni A; Cirami C
Transpl Infect Dis; 2020 Aug; 22(4):e13286. PubMed ID: 32279418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]